AUTHOR : Daanya katerwala .<\/p>\n
INTRODUCTION : Dr. Reddy’s Laboratories<\/strong>\u00a0is an Indian multinational\u00a0pharmaceutical<\/a>\u00a0company based in\u00a0Hyderabad<\/a>. The company was founded by\u00a0Kallam Anji Reddy<\/a>, who previously worked in the mentor institute\u00a0Indian Drugs and Pharmaceuticals Limited<\/a>. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60\u00a0active pharmaceutical ingredients<\/a>\u00a0(APIs) for drug manufacture, diagnostic kits,\u00a0critical care<\/a>, and\u00a0biotechnology<\/a>.<\/p>\n Dr. Reddy’s began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a\u00a0manufacturing plant<\/a>\u00a0that would gain approval from a drug licensing body such as the\u00a0U.S. Food and Drug Administration<\/a>\u00a0(FDA). By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants \u2013 in more-developed economies. This allowed their movement into regulated markets such as the US and\u00a0Europe<\/a>.<\/p>\n By 2007, Dr. Reddy’s had seven FDA plants producing active pharmaceutical ingredients in India and seven\u00a0FDA<\/a>-inspected and\u00a0ISO 9001<\/a>\u00a0(quality) and\u00a0ISO 14001<\/a>\u00a0(environmental management) certified plants making patient-ready medications \u2013 five of them in India and two in the UK.<\/p>\n \u00a0<\/p>\n 1 . TITLE : \u201c Dr Reddy’s Laboratories launches Difluprednate Ophthalmic Emulsion in the US market .\u201d<\/p>\n Free press journal ; Mumbai .<\/p>\n The equivalent Durezol brand and generic had U.S. sales of approximately $40 million MAT for the most recent twelve months ending in November 2022 according to IQVIADr.\u00a0Reddy\u2019s\u00a0Laboratories\u00a0Ltd, today announced the launch of\u00a0Dr.\u00a0Reddy\u2019s Difluprednate Ophthalmic Emulsion 0.05%, a therapeutic generic equivalent to Durezol (Difluprednate Ophthalmic Emulsion 0.05%) in the U.S. market, via an exchange filing.The announcement is following the approval by the U.S. Food and Drug Administration (USFDA).The Durezol brand and generic had U.S. sales of approximately $40 million MAT for the most recent twelve months ending in November 2022 according to IQVIA.Dr.\u00a0Reddy\u2019s Difluprednate Ophthalmic Emulsion 0.05% is available in 5 ml bottles in case packs of 24.<\/p>\n Life Insurance Corporation of India on Tuesday informed through an exchange filing that the Corporation\u2019s shareholding in\u00a0Dr\u00a0Reddy’s\u00a0Laboratories\u00a0Limited has diluted from 1,61,44,983 to 1,27,20,873 Equity Shares, decreasing its shareholding from 9.681 percent to 7.628 percent of the paid-up capital of the said Company.<\/p>\n The company in the regulatory filing said that the holding decreased from 9.681 percent to 7.628 percent, a decrease of 2.053 percent during the period from March 10, 2023 to September 11, 2023 at an average cost of Rs 5705.43<\/p>\n Dr.\u00a0Reddy’s\u00a0Laboratories\u00a0Ltd is a pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APls), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.<\/p>\n DATA COLLECTION : The data for Nifty and Equity for Dr. Reddy\u2019s Laboratories Ltd has been downloaded from Nse.com and Yahoo.finance.com for the period 1st<\/sup> Nov 2022 \u2013 31st<\/sup> Oct 2023 . The data was manipulated for closing price of Nifty and Equity . The weekly returns of Nifty and Equity were found .\u00a0<\/p>\n DATA ANALYSIS :<\/p>\n2 . TITLE : \u201cLIC Reduces Stake In Dr Reddy’s Laboratories From 9.68% To 7.63%\u201d.<\/h1>\n